Category: 8. Health

June 2025 delivered pivotal updates across the field of women’s health, spanning clinical guidance, therapeutic innovation, policy statements, and new research insights.

From ACOG’s condemnation of violence against reproductive health providers to promising trial data on managing vasomotor symptoms and recurrent bacterial vaginosis, this month’s developments reflect both the clinical and societal forces shaping OB/GYN practice today. Additional highlights include updated AAP recommendations on adolescent contraceptive care and new findings linking ADHD to increased risk of premenstrual dysphoric disorder.

In this monthly roundup, Contemporary OB/GYN summarizes the most significant clinical findings, expert commentary, and policy developments from June 2025.

Click on each headline below for full coverage and analysis.

1. Elinzanetant found to reduce VMS from endocrine therapy for breast cancer

A phase 3 trial published in the New England Journal of Medicine found that elinzanetant significantly reduced moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for hormone receptor–positive breast cancer. Among the 474 participants, those receiving elinzanetant reported up to 3.5 fewer daily hot flash episodes by week 4 compared to placebo. Improvements in sleep and menopausal quality of life were also greater in the elinzanetant group. These findings address a critical need, as vasomotor symptoms often undermine adherence to endocrine therapy, potentially affecting long-term cancer outcomes.

2. Secnidazole shows promise for recurrent BV treatment in new clinical trial

New data presented at the 2025 ACOG Annual Clinical and Scientific Meeting support the long-term use of secnidazole oral granules for recurrent bacterial vaginosis (BV), a condition affecting nearly 1 in 3 reproductive-aged women in the U.S. In a small trial, once-weekly 2 g doses showed comparable or improved efficacy to CDC-recommended suppressive regimens. Lead investigator Chemen M. Neal, MD, emphasized the potential for simplified dosing to improve adherence and reduce recurrence. The findings also underscore the need for accurate diagnosis and sustained management of BV, which carries both physical and psychosocial burdens.

3. ACOG condemns violence against reproductive health care providers

In a joint statement, ACOG president Steven J. Fleischman, MD, and CEO Sandra E. Brooks, MD, condemned recent acts of violence targeting reproductive health care providers, including a bombing at a Minnesota fertility clinic and online harassment of clinicians. The statement, released following the 2025 ACOG Annual Clinical and Scientific Meeting, underscored the escalating risks ob-gyns face for delivering comprehensive reproductive care. Citing long-standing patterns of ideologically motivated violence, ACOG called for strengthened protections under policies like the Freedom of Access to Clinic Entrances Act and urged political leaders to oppose threats against providers.

4. AAP issues updated guidance on contraception for adolescents

The American Academy of Pediatrics updated its guidance on adolescent contraceptive care, urging pediatricians to provide developmentally appropriate, confidential counseling and access to the full spectrum of contraceptive methods. Published in the July 2025 issue of Pediatrics, the policy emphasizes equity, autonomy, and shared decision-making. The AAP highlights the need for proactive engagement given persistent gaps in contraceptive use among teens and calls for expanded access through telehealth and school-based care. Pediatricians are also encouraged to integrate contraception discussions with broader sexual health care, including STI screening and HPV vaccination.

5. ADHD linked to higher risk of premenstrual dysphoric disorder

Women with ADHD may face a significantly higher risk of premenstrual dysphoric disorder (PMDD), according to new findings published in the British Journal of Psychiatry. Using survey data from U.K. participants, researchers found PMDD symptoms were over three times more likely in women with ADHD, and risk was even higher when anxiety or depression was also present. PMDD was identified in 31.4% of those with ADHD versus 9.8% of those without. The study’s authors called for increased screening and a better understanding of how hormonal changes affect women with ADHD to address diagnostic disparities.

Using an inexpensive electrode coated with DNA, MIT researchers have designed disposable diagnostics that could be adapted to detect a variety of diseases, including cancer or infectious diseases such as influenza and HIV.

These electrochemical sensors make use of a DNA-chopping enzyme found in the CRISPR gene-editing system. When a target such as a cancerous gene is detected by the enzyme, it begins shearing DNA from the electrode nonspecifically, like a lawnmower cutting grass, altering the electrical signal produced.

One of the main limitations of this type of sensing technology is that the DNA that coats the electrode breaks down quickly, so the sensors can’t be stored for very long and their storage conditions must be tightly controlled, limiting where they can be used. In a new study, MIT researchers stabilized the DNA with a polymer coating, allowing the sensors to be stored for up to two months, even at high temperatures. After storage, the sensors were able to detect a prostate cancer gene that is often used to diagnose the disease.

The DNA-based sensors, which cost only about 50 cents to make, could offer a cheaper way to diagnose many diseases in low-resource regions, says Ariel Furst, the Paul M. Cook Career Development Assistant Professor of Chemical Engineering at MIT and the senior author of the study.

“Our focus is on diagnostics that many people have limited access to, and our goal is to create a point-of-use sensor. People wouldn’t even need to be in a clinic to use it. You could do it at home,” Furst says.

MIT graduate student Xingcheng Zhou is the lead author of the paper, published June 30 in the journal ACS Sensors. Other authors of the paper are MIT undergraduate Jessica Slaughter, Smah Riki ’24, and graduate student Chao Chi Kuo.

An inexpensive sensor

Electrochemical sensors work by measuring changes in the flow of an electric current when a target molecule interacts with an enzyme. This is the same technology that glucose meters use to detect concentrations of glucose in a blood sample.

The electrochemical sensors developed in Furst’s lab consist of DNA adhered to an inexpensive gold leaf electrode, which is laminated onto a sheet of plastic. The DNA is attached to the electrode using a sulfur-containing molecule known as a thiol.

In a 2021 study, Furst’s lab showed that they could use these sensors to detect genetic material from HIV and human papillomavirus (HPV). The sensors detect their targets using a guide RNA strand, which can be designed to bind to nearly any DNA or RNA sequence. The guide RNA is linked to an enzyme called Cas12, which cleaves DNA nonspecifically when it is turned on and is in the same family of proteins as the Cas9 enzyme used for CRISPR genome editing.

If the target is present, it binds to the guide RNA and activates Cas12, which then cuts the DNA adhered to the electrode. That alters the current produced by the electrode, which can be measured using a potentiostat (the same technology used in handheld glucose meters).

“If Cas12 is on, it’s like a lawnmower that cuts off all the DNA on your electrode, and that turns off your signal,” Furst says.

In previous versions of the device, the DNA had to be added to the electrode just before it was used, because DNA doesn’t remain stable for very long. In the new study, the researchers found that they could increase the stability of the DNA by coating it with a polymer called polyvinyl alcohol (PVA).

This polymer, which costs less than 1 cent per coating, acts like a tarp that protects the DNA below it. Once deposited onto the electrode, the polymer dries to form a protective thin film.

“Once it’s dried, it seems to make a very strong barrier against the main things that can harm DNA, such as reactive oxygen species that can either damage the DNA itself or break the thiol bond with the gold and strip your DNA off the electrode,” Furst says.

Successful detection

The researchers showed that this coating could protect DNA on the sensors for at least two months, and it could also withstand temperatures up to about 150 degrees Fahrenheit. After two months, they rinsed off the polymer and demonstrated that the sensors could still detect PCA3, a prostate cancer gene that can be found in urine.

This type of test could be used with a variety of samples, including urine, saliva, or nasal swabs. The researchers hope to use this approach to develop cheaper diagnostics for infectious diseases, such as HPV or HIV, that could be used in a doctor’s office or at home. This approach could also be used to develop tests for emerging infectious diseases, the researchers say.

A group of researchers from Furst’s lab was recently accepted into delta v, MIT’s student venture accelerator, where they hope to launch a startup to further develop this technology. Now that the researchers can create tests with a much longer shelf-life, they hope to begin shipping them to locations where they could be tested with patient samples.

“Our goal is to continue to test with patient samples against different diseases in real world environments,” Furst says. “Our limitation before was that we had to make the sensors on site, but now that we can protect them, we can ship them. We don’t have to use refrigeration. That allows us to access a lot more rugged or non-ideal environments for testing.”

The research was funded, in part, by the MIT Research Support Committee and a MathWorks Fellowship.

PROVIDENCE, R.I. [Brown University] — Sunscreen should be simple: Apply it properly, and it will do its job shielding skin from the sun’s damaging rays. Yet despite the fact that sunscreen has enjoyed popularity for decades — and that it’s recommended for universal use by the American Academy of Dermatology — it is often misunderstood and misused.

Dr. Elnaz Firoz, an associate professor of dermatology, clinician educator, at Brown University’s Warren Alpert Medical School, and medical director of dermatology at Miriam Hospital in Providence, said she spots dozens of sunscreen use mistakes every time she goes to the beach.

“I’m always so shocked at the practices that I see,” Firoz said. “It makes me wonder how we can get more information out to people about how to use sunscreen.”

One way to educate people about sun protection is to connect them with dermatologists. Firoz is one of several Brown-affiliated faculty members who participate in free skin cancer screenings, including at the Amal Clinic at Clínica Esperanza, the Rhode Island Free Clinic and a series of skin check events held at Rhode Island beaches in partnership with the Rhode Island Department of Health.

In this Q&A, Firoz shares sun protection advice and addresses myths about the dangers of sunscreen.

Q: What are the biggest mistakes people make when it comes to using sunscreen?

It’s very common for people at the beach to use aerosol bottles of “invisible” chemical sunscreen. Most of the product ends up getting sprayed into the air instead of on the skin, thereby providing less coverage than intended. People will also use the spray sunscreen on faces, where it can get in the eyes, nose and mouth, and cause stinging or a terrible aftertaste. I understand that the spray version is convenient, but it can be difficult to use it in a way that provides adequate protection.

Q: What type of sunscreen do you recommend?

I advise my patients to find a broad-spectrum — meaning it protects against both UVA and UVB sun rays — mineral sunscreen with a sun protection factor (SPF) of at least 30. There are two main product formulations: mineral sunscreens, which have ingredients like zinc oxide and titanium dioxide that sit on the top layer of your skin and block and reflect UV rays; and chemical sunscreens, which sink into your skin and act like sponges, absorbing the sun’s UV rays. Chemical sunscreens are somewhat less photostable than mineral sunscreens, which means they degrade over time slightly more quickly as they are exposed to UV radiation.

I’m a big fan of mineral sunscreen lotion, which is not only broad-spectrum but also safe, and lasts longer both in and out of the water. Mineral formulations tend to be thicker and some may leave a whitish cast on the skin, but technology has advanced to the point that there are now tinted and untinted mineral sunscreens that go on quite easily. 

Q: In your practice, what implications for patients do you see as a result of not wearing sunscreen?

The main reason to use sunscreen is to prevent skin cancer. All types of skin cancer, including basal cell carcinoma, squamous cell carcinoma and melanoma, are unfortunately on the rise. Melanoma is especially worrisome because it can metastasize if not caught early and become fatal, which is why we urge people to get skin checks. Squamous cell carcinoma can also be fatal (albeit rarely), particularly in patients who are elderly or immunocompromised. 

UV radiation is a carcinogen — we know that to be 100% true. Each person is going to withstand that carcinogen differently based on their genetics and behavioral practices. And there are, of course, subtypes of melanoma that are not related to the sun. But I tell patients that generally speaking, their risk for skin cancer will be lower if they practice sun safe behaviors, which includes wearing sunscreen. Wearing sunscreen also slows the process of sun damage to the skin. 

NEW DELHI: Imagine a routine blood donation quietly holding evidence of a future cancer diagnosis. A recent study published in Cancer Discovery suggests that could soon be a reality: scientists have found cancer-linked DNA mutations in blood plasma collected years before patients showed any signs of disease.In a groundbreaking analysis, Dr Yuxuan Wang and her team at Johns Hopkins University examined plasma samples donated as part of an unrelated study decades ago. By analyzing free-floating DNA fragments, the genetic leftovers from dying cells, they were able to spot warning signs of cancer as far back as 3.5 years before diagnosis, the recent study published on May 22 in the journal Cancer Discovery mentioned.

“It’s an important step toward preclinical cancer detection,” said Catherine Alix-Panabières, a cancer researcher not involved in the study. “Earlier detection typically means better outcomes.”The research focused on 52 people: 26 who developed cancer within six months of donating blood, and 26 who remained cancer-free for at least 17 years. In seven of the cancer patients’ samples, researchers detected common cancer mutations, and in two cases, those same mutations were already present years before any tumors were found.The team dove deeper, sequencing DNA from earlier samples and comparing them to the patients’ white blood cells. In three cases, they uncovered dozens of unique genetic mutations, all hinting at cancer in its earliest molecular form.These findings, though early, shine a spotlight on blood plasma as a potential early-warning system, a kind of molecular time machine. The cancers detected ranged from breast and colon to pancreatic and liver, though some types, like brain cancer, remain elusive due to biological barriers like the blood-brain barrier.Still, it’s not all breakthroughs and optimism.“We didn’t find any mutations in 18 out of 26 cancer patients,” Dr Wang admitted, pointing to the need for larger plasma samples and better detection tools. Cost is another barrier; identifying personalized mutations through DNA sequencing can cost hundreds to thousands of dollars per patient.While full-scale clinical use may be 5–10 years away, experts are cautiously hopeful. With larger trials and stricter ethical guidelines, such tests might one day become routine for high-risk groups, giving doctors a head start before cancer gets one.For now, the study offers a glimpse into a future where a simple blood draw could change the story of cancer, long before the first symptom ever appears.